Business
Lifeward Successfully Closes on Strategic Partnership with Oramed
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation compan
About this update from Lifeward Ltd.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed’s clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to $47 million of capital from Oramed and certain investors, and on March 25, 2026 Lifeward accessed $10 million of such capital. The Company has also made changes to its board of directors. More information about the closing of the transaction may be viewed in Lifeward’s Form 8-K filed on March 25, 2026. About Lifeward Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com. Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934 concerning L...